IP Library › Granted Patent US 12,215,141
Granted Patent B2
US 12,215,141 · App. 17/931,629 · Granted Feb 4, 2025

Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Inventor: Laura M. Walker (Lebanon, NH)
Assignee: ADIMAB, LLC
C07K16/1027A61K39/42A61P31/16C07K2317/33C07K2317/34C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,215,141
App. No.
17/931,629
Granted
Feb 4, 2025
Kind
B2
Abstract

Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as nucleic acid sequences encoding such antibodies, methods for their identification, isolation, generation, and methods for their preparation and use are provided.

Claims (20)

1. An isolated antibody or an antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) F protein (F) (“anti-RSV F antibody”), wherein said antibody:

(i) comprises a heavy chain (HC) polypeptide comprising a variable heavy (V H) chain polypeptide comprising VH CDR1, 2 and 3 polypeptides respectively comprising the amino acid sequences of SEQ ID NO: 51, 53 and 55; and a light chain (LC) polypeptide comprising a variable light (VL) chain polypeptide comprising VL CDR1, 2 and 3 polypeptides respectively comprising the amino acid sequences of SEQ ID NO: 59, 61 and 63; or

(ii) comprises a HC polypeptide comprising a VH chain polypeptide comprising VH CDR1, 2 and 3 polypeptides respectively comprising the amino acid sequences of SEQ ID NO: 979, 981 and 983; and a LC polypeptide comprising a VL chain polypeptide comprising VL CDR1, 2 and 3 polypeptides respectively comprising the amino acid sequences of SEQ ID NO:987, 989 and 991.

2. The isolated anti-RSV F antibody of claim 1 , which comprises either:

(i)

(1) a VH chain polypeptide comprising the same VH CDRs as recited in claim 1 (i) and possessing at least 90% sequence identity or at least 95% sequence identity to the VH chain polypeptide of SEQ ID NO: 50; and

(2) a VL chain polypeptide comprising the same VL CDRs as recited in claim 1 (i), and possessing at least 90% sequence identity, or at least 95% sequence identity to SEQ ID NO: 58: or

(ii)

(1) a VH chain polypeptide comprising the same VH CDRs as recited in claim 1 (ii), and possessing at least 90% sequence identity, or at least 95% sequence identity to the VH chain polypeptide of SEQ ID NO: 978; and

(2) a VL chain polypeptide comprising the same VL CDRs as recited in claim 1 (ii), and possessing at least 90% sequence identity to the VL chain polypeptide of SEQ ID NO: 986.

3. The isolated anti-RSV F antibody of claim 1 , which comprises either:

(i) a VH chain polypeptide comprising the amino acid sequence of SEQ ID NO: 50; and a VL chain polypeptide comprising the amino acid sequence of SEQ ID NO: 58: or

(ii) a VH chain polypeptide comprising the amino acid sequence of SEQ ID NO: 978; and a variable light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 986.

4. A pharmaceutical composition comprising the anti-RSV F antibody of claim 1 ; and a pharmaceutically acceptable carrier and/or excipient.

5. A method for (i) preventing a respiratory syncytial virus (RSV) infection in a patient in need thereof or suspected of being in need thereof, or for treating a patient suffering from an RSV infection, or for ameliorating at least one symptom or complication associated with the infection, wherein the infection is either prevented, or at least one symptom or complication associated with the infection is prevented, ameliorated, or lessened in severity and/or duration as a result of such use; or (ii) treating or preventing either a RSV infection or a human metapneumovirus (HMPV) infection, or at least one symptom associated with the RSV infection or the HMPV infection, in a patient in need thereof or suspected of being in need thereof, by administering an anti-RSV F antibody according to claim 1 .

6. The method according to claim 5 , which further comprises administering to the patient a second therapeutic agent optionally selected from the group consisting of an antiviral agent; a vaccine specific for RSV, a vaccine specific for influenza virus, or a vaccine specific for metapneumovirus (MPV); an siRNA specific for an RSV antigen or a metapneumovirus (MPV) antigen; a second antibody specific for an RSV antigen or a metapneumovirus (MPV) antigen; an anti-IL4R antibody, an antibody specific for an influenza virus antigen, an anti-RSV-G antibody, and a NSAID.

7. A pharmaceutical composition comprising the anti-RSV F antibody of claim 2 ; and a pharmaceutically acceptable carrier and/or excipient.

8. A pharmaceutical composition comprising the anti-RSV F antibody of claim 3 ; and a pharmaceutically acceptable carrier and/or excipient.

9. A method for (i) preventing a respiratory syncytial virus (RSV) infection in a patient in need thereof or suspected of being in need thereof, or for treating a patient suffering from an RSV infection, or for ameliorating at least one symptom or complication associated with the infection, wherein the infection is either prevented, or at least one symptom or complication associated with the infection is prevented, ameliorated, or lessened in severity and/or duration as a result of such use; or (ii) treating or preventing either a RSV infection or a human metapneumovirus (HMPV) infection, or at least one symptom associated with the RSV infection or the HMPV infection, in a patient in need thereof or suspected of being in need thereof, by administering an anti-RSV F antibody according to claim 2 .

10. A method for (i) preventing a respiratory syncytial virus (RSV) infection in a patient in need thereof or suspected of being in need thereof, or for treating a patient suffering from an RSV infection, or for ameliorating at least one symptom or complication associated with the infection, wherein the infection is either prevented, or at least one symptom or complication associated with the infection is prevented, ameliorated, or lessened in severity and/or duration as a result of such use; or (ii) treating or preventing either a RSV infection or a human metapneumovirus (HMPV) infection, or at least one symptom associated with the RSV infection or the HMPV infection, in a patient in need thereof or suspected of being in need thereof, by administering an anti-RSV F antibody according to claim 3 .

Continuity (3)
Division 16343273
Provisional Application 62411510 · Oct 21, 2016
Related Publication 20230303668A1 · Sep 28, 2023
References Cited (45)
US 5866125A · Brams et al. · 1999 [cited by applicant]
US 10259874B2 · Wang et al. · 2019 [cited by applicant]
US 20020141990A1 · Deen et al. · 2002 [cited by applicant]
US 20160024188A1 · van den Brink · 2016 [cited by applicant]
US 20190256580A1 · Walker · 2019 [cited by applicant]
US 20190256581A1 · Walker · 2019 [cited by applicant]
US 20200223906A1 · Walker · 2020 [cited by applicant]
JP 2010534057 · 2010 [cited by applicant]
JP 2011514139 · 2011 [cited by applicant]
JP 2020503844 · 2020 [cited by applicant]
WO 2008106980 · 2008 [cited by applicant]
WO 2009030237 · 2009 [cited by applicant]
WO WO2014121021A1 · 2014 [cited by applicant]
WO 2015108967 · 2015 [cited by applicant]
WO 2018075961 · 2018 [cited by applicant]
WO 2018075974 · 2018 [cited by applicant]
Van Mechelen et al., Antiviral Research vol. 132, pp. 1-5 (Year: 2016). [cited by examiner]
Casset et al. “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design.” Biochemical and biophysical research communications. Jul. 18, 2003;307(1):198-205. [cited by applicant]
Van Mechelen et al. “RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors.” Antiviral Research. Aug. 1, 2016;132:1-5. [cited by applicant]
McLellan, Jason S et al. “Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.” Science (New York, N.Y.) vol. 340,6136 (2013): 1113-7. doi: 10.1126/science. 1234914. [cited by applicant]
Casset, F. et al., A peptide mimetic of an anti-CD4 monoclonal antibody by rational design, Biochemical and Biophysical Research Communications, 307:198-205 (2003). [cited by applicant]
Colman, Peter M., Effects of amino acid sequence changes on antibody-antigen interactions, Research in Immunology, 145:33-36 (1994). [cited by applicant]
Gilman, Morgan S A et al. “Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors.” Science immunology vol. 1,6 (2016): eaaj1879. doi:10.1126/sciimmunol.aaj1879. [cited by applicant]
International Search Report for PCT/US2017/057737 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filed Oct. 20, 2017), issued by ISA/EP, 10 pages (Aug. 30, 2018). [cited by applicant]
International Search Report for PCT/US2017/057720 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filed Oct. 20, 2017), issued by ISA/EPO, 10 pages (Mar. 13, 2018). [cited by applicant]
Janeway, C. et al., Immunobiology: The Immune System in Health and Disease, 5 pages (2005). [cited by applicant]
Liang, B. et al., Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate, Journal of Virology, 89(18):9499-9510 (2015). [cited by applicant]
Liang, B. et al., Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed… [cited by applicant]
Magro, M. et al., Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention, Proc Natl Acad Sci USA, 109(8):3089-94 (2012). [cited by applicant]
Mechelen, L. et al., RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors, Antiviral Research, 132:1-5 (2016). [cited by applicant]
Paul, William E., Fundamental Immunology, 3rd Edition, pp. 292-295 (1993). [cited by applicant]
Raghunandan, R. et al., An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immuni… [cited by applicant]
Rudikoff, S. et al., Single amino acid substitution altering antigen-binding specificity, Proc. Natl. Acad. Sci. USA, 79:1979-1983 (1982). [cited by applicant]
Sela-Culang, I. et al., The structural basis of antibody-antigen recognition, Frontiers in Immunology, 4: 13 pages (2013). [cited by applicant]
Stryer, Lubert, Biochemistry, 4th Edition, WH Freeman and Company, New York, 8 pages (1995). [cited by applicant]
Written Opinion for PCT/US2017/057737 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filed Oct. 20, 2017), issued by ISA/EP, 14 pages (Aug. 30, 2018). [cited by applicant]
Written Opinion for PCT/US2017/057720 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filed Oct. 20, 2017), issued by ISA/EPO, 12 pages (Mar. 13, 2018). [cited by applicant]
Huang, Jiachen et al. “Antibody Epitopes of Pneumovirus Fusion Proteins.” Frontiers in immunology vol. 10 2778. Nov. 29, 2019, doi:10.3389/fimmu.2019.02778. [cited by applicant]
Corti, D. et al., Cross-neutralization of four paramyxoviruses by a human monoclonal antibody, Nature, 501(7467):439-443 (2013). [cited by applicant]
Giersing, B. et al., Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, Apr. 25-26, 2016, Vaccine, 8 pages (2017). [cited by applicant]
International Search Report for PCT/US17/57708 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filed Oct. 20, 2017), issued by ISA/EP, 10 pages (Aug. 30, 2018). [cited by applicant]
Mclellan, Jason S., Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein, Current Opinion in Virology, 11:70-75 (2015). [cited by applicant]
Ngwuta, J. et al., Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera, Science Translational Medicine, 7(309):309ra162-309ra162 (2015). [cited by applicant]
Schuster, J. et al., A Broadly Neutralizing Human Monoclonal Antibody Exhibits In Vivo Efficacy Against Both Human Metapneumovirus and Respiratory Syncytial Virus, Journal of Infectious Diseases, 211(2):216-225 (2014). [cited by applicant]
Written Opinion for PCT/US17/57708 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filed Oct. 20, 2017), issued by ISA/EP, 15 pages (Aug. 30, 2018). [cited by applicant]